HDAC - Melanoma - Multiple Myeloma - Renal Cancer
Histone deacetylases (HDACs), known for their ability to target histones as well as more than 50 non-histone proteins, are classified into three major classes according to their homology to yeast proteins, including class I (HDAC1, HDAC2, HDAC3 and HDAC8), class II (HDAC4, HDAC5, HDAC7 and HDAC9) and class IV (HDAC11). HDAC inhibitors, a large group of compounds that is able to induce the accumulation of acetylated histones as well as non-histone proteins, are divided into several structural classes including hydroxamates, cyclic peptides, aliphatic acids and benzamides. HDAC inhibitors have been investigated for their efficacy as anticancer agents in the treatment of a wild range of cancers.
清除全部
- A4094 MC15683 CitationTarget: Histone Deacetylases (HDACs)Summary: II类HDAC抑制剂
- A4093 ITF2357 (Givinostat)2 CitationTarget: Histone Deacetylases (HDACs)Summary: HDAC抑制剂
- A4083 Rocilinostat (ACY-1215)1 CitationTarget: Histone Deacetylases (HDACs)Summary: 选择性的HDAC6抑制剂
- A8173 Romidepsin (FK228, depsipeptide)7 Citation中文名: 罗米地辛Target: Histone Deacetylases (HDACs)Summary: 选择性的HDAC1/HDAC2抑制剂
- A8178 Panobinostat (LBH589)10 Citation中文名: 帕比司他Target: Histone Deacetylases (HDACs)Summary: HDAC抑制剂